Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Shortage Senate Draft: FDA Told To Look For Impact Before Leaping Into Enforcement

Executive Summary

Proposal would require shortage consideration before FDA issues an enforcement action, which could ensure enforcement and shortage staff continue talking.

You may also be interested in...



Orphan Antibiotics? Woodcock Says It May Be Possible If IDSA’s New Pathway Is Implemented

CDER director says SPLMU proposal could open up antibiotics for resistant pathogens to orphan drug incentives, which could help prime the anemic development pipeline.

Drug Shortage Legislation: Sen. Blumenthal Calls For More Extensive Effort

Democratic Senator has terse exchange with FDA at hearing and says Congress must do more than what is already in pending legislation. Blumenthal said he is willing to consider the Generic Pharmaceutical Association proposal calling for an independent third party to compile supplier data and predict coming shortages.

Drug Shortage Provisions In Draft PDUFA Bill Would Expedite Major Manufacturing Changes

FDA would have 60 days to review major changes and could “deem” them compliant with current good manufacturing practices so long as the facility has a plan and resources to achieve full compliance and institutes quality control measures under draft legislation being developed by the House Energy and Commerce Committee.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS054362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel